SRP-9001 Fails to Meet Primary End Point in Phase 3 EMBARK Study
Over a 52-week treatment period, SRP-9001 demonstrated robust evidence for a clinically meaningful benefit across several prespecified functional secondary end points in comparison with placebo.
Doug Ingram
Months after the FDA approved Sarepta Therapeutics’ gene therapy SRP-9001 (Elevidys) for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD), the company has announced topline data from the phase 3 EMBARK study (NCT05096221), a trial aimed to reinforce the agent’s efficacy. Full results from EMBARK are expected to be shared at a future medical meeting and publication will be pursued in a medical journal.1
Data from the 2-part, crossover, placebo-controlled study showed that patients with DMD aged 4 to 7 years old improved 2.6 points on the North Star Ambulatory Assessment (NSAA) total score, the primary end point, 52 weeks after treatment started. In comparison, those on placebo improved 1.9 points, a difference of 0.65-points that was not statistically significant between groups (P = .24). In addition, treatment with the therapy resulted in robust changes on all key pre-specified functional secondary end points over the treatment period.
"The results of EMBARK, our double-blind, placebo-controlled trial, support the conclusion that Elevidys modifies the trajectory of Duchenne and benefits patients across age groups living with this ferociously degenerative disease," Doug Ingram, president and chief executive officer at Sarepta, said in a statement.1 "The results favored Elevidys across all endpoints in the study, including achieving statistical significance on all pre-specified key secondary endpoints and in each age subgroup of the key secondary endpoints. Indeed, passing 5 seconds on time to rise is the strongest predictor of early loss of ambulation and in EMBARK, Elevidys reduced those odds over 52 weeks by greater than 90 percent."
In EMBARK, eligible patients received a single dose of SRP-9001 during either Part 1 or Part 2 of the study. In Part 1, participants (n = 125) were randomized according to age (≥4 to <8 years) or NSAA total score at screening (>16 or <29) and received either 1.33 x 1014 vg/kg of SRP-9001 or placebo with a follow-up period for 52 weeks. Following Part 1, patients crossed over to the opposite treatment for Part 2 of the study, where they are followed for 52 weeks. All patients remain blinded.1
Across secondary end points, investigators recorded a least square mean (LSM) difference of –0.64 (P = .0025) in change on time to rise (TTR) for SRP-9001-treated patients vs placebo. The effects of the agent were more pronounced among 6- and 7-year-old treated patients (LSM change vs placebo, –0.78; P = .0291) than among patients aged 4-5 (LSM change vs placebo, –.50; P = .0177). Similarly, the agent resulted in clinically meaningful treatment effects on 10-meter walk test (LSM change vs placebo, –0.42; P = .0048), with higher impacts observed among those aged 6-7 years old (LSM change vs placebo, –0.52; P = .0363) than those aged 4-5 years old (LSM change vs placebo, –0.33; P = .0319).
"Based on the EMBARK results, we intend to move swiftly to request an update to expand the labeled indication to treat all patients," Ingram added.1 "Importantly, we have shared the EMBARK topline results with FDA leadership and they have confirmed that, based on the totality of the evidence, they are open to such label expansion if supported by review of the data, and that they intend to proceed rapidly with consideration of the submission."
READ MORE: An Inside Look at the 11th Annual Miami Neuroscience Symposium
According to the update, there were no new observed safety signals in the trial, with a safety profile that was consistent to SRP-9001 to date. The most common treatment-related adverse events were gastrointestinal events, including vomiting, nausea, and decreased appetite, as well as pyrexia. Seven participants (11.1%) experienced a treatment-related serious adverse events and there were no clinically meaningful changes observed in SAEs associated with the known risks of SRP-9001.
SRP-9001, otherwise known as delandistrogene moxeparvovec, was approved by the FDA earlier this year as the first gene therapy for patients with DMD with a confirmed mutation in the DMD gene. An AAV vector-based gene therapy, SRP-9001 was approved based on data from several studies, including the phase 1/2 SRP-9001-101 (NCT03375164), the phase 2 SRP-9001-102 study, and the phase 1 ENDEAVOR study (SRP-9001-103; NCT04626674). The medication is indicated for ambulatory pediatric patients aged 4 to 5 years with DMD and is contraindicated for those with any deletion in exon 8 and/or exon 9 in the DMD gene.
"The strong prognostic power of time to rise, and the particular importance of the 5 second milestone in predicting functional decline and future loss of ambulation, is clearly demonstrated in natural history. In EMBARK, the reduction in patients progressing past this milestone when treated with Elevidys is highly clinically relevant," Craig McDonald, MD, professor and chair of the UC Davis Health Department of Physical Medicine and Rehabilitation, and an investigator of EMBARK, said in a statement.1 "The consistency of the positive effect across all timed function tests and age groups provides evidence of a meaningful treatment effect. In addition, it is important to note that this is the first clinical trial in the history of DMD trials to show a statistically significant and meaningful improvement on the novel measure of 95th centile stride velocity derived from an objective community wearable activity monitor."
